BioSpace News Archive

Drug Development

Carmot Therapeutics Initiates the Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Patients with Type 2 Diabetes

Carmot Therapeutics, Inc. announced today the initiation of the phase 1 study for CT-388, a once weekly, fully biased dual GLP-1 and GIP receptor modulator, in otherwise healthy overweight and obese participants.

June 24, 2021
·
4 min read
FDA

Santen Receives FDA Approval for Verkazia™ (Cyclosporine Ophthalmic Emulsion) 0.1% for the Treatment of Vernal Keratoconjunctivitis in Children and Adults

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on eye care, announced that the U.S. Food and Drug Administration has approved Verkazia™ 0.1% eye drops for the treatment of vernal keratoconjunctivitis in children and adults.

June 24, 2021
·
4 min read
Business

Appili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results and Provides Update on Strategy for Fiscal 2022

Appili Therapeutics Inc. today announced its financial and operational results for the fiscal year ended March 31, 2021, and provided an update on the Company’s strategy for fiscal 2022.

June 24, 2021
·
6 min read
Business

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

Intellia Therapeutics, Inc. today announced the appointment of James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary.

June 24, 2021
·
5 min read
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Innovations Group today announced that it has selected substance use disorder and smoking cessation as the initial target indications for its proprietary psychedelic molecule MYCO-004.

June 24, 2021
·
7 min read
Biotech Beach

New Science 37® Report: Nearly 100% of Biopharma Executives Expect Clinical Trial Decentralization to Increase Yet Lack Internal Capabilities to Operationalize

New Science 37 ® Report: Nearly 100% of Biopharma Executives Expect Clinical Trial Decentralization to Increase Yet Lack Internal Capabilities to Operationalize

June 24, 2021
·
3 min read
Genetown

Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class

Blood Test Predicts TNFi Response in Patients Both Naïve to and Experienced with Therapy Providers Can Access Patient-Specific Data for Optimized Therapy Selection.

June 24, 2021
·
4 min read
Pharm Country

Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone

PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA® (deflazacort) over prednisone for the treatment of Duchenne muscular dystrophy (DMD).

June 24, 2021
·
8 min read
Policy

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

Shenzhen Chipscreen Biosciences’ licensing partner, HUYABIO International, announced the regulatory approval for Tucidinostat monotherapy of relapsed or refractory adult T-cell leukemia/lymphoma by the Japanese Pharmaceuticals and Medical Devices Agency.

June 24, 2021
·
2 min read
Deals

Boston Scientific Exercises Option to Acquire Farapulse, Inc.

Boston Scientific Corporation announced it exercised its option to acquire the remaining shares of Farapulse, Inc.

June 24, 2021
·
6 min read